When the Children’s Oncology Group, the largest pediatric cancer research consortium in the world, stopped a clinical trial early so more kids could access the treatment immediately, it sent a clear message: this is a breakthrough.
That treatment is blinatumomab. And it’s now the new standard of care for kids with high-risk acute lymphoblastic leukemia (ALL).
This didn’t happen by chance. It happened because people chose to give.
Every act of generosity starts with heart. And giving in ways like stock, crypto, or from your IRA? That’s heart and smart—for kids, and for you.
Find your tax-smart way to fund the next breakthrough.
